Invest now
Aurobindo Pharma share price
Moderate risk
You have to be logged in to add this to Watchlist.- ₹1,658.65(-0.98%)October 16, 2026 15:13:39 PM IST
- NSE
- BSE
- Vol : 807.85 K (NSE + BSE)Last 20 day avg : 911.48 K
Aurobindo Pharma is trading -0.98% lower at Rs 1,658.65 as compared to its last closing price. Aurobindo Pharma has been trading in the price range of 1,683.55 & 1,654.75. Aurobindo Pharma has given 41.83% in this year & 2.00% in the last 5 days. Aurobindo Pharma has TTM P/E ratio 24.67 as compared to the sector P/E of 33.15.There are 26 analysts who have initiated coverage on Aurobindo Pharma. There are 8 analysts who have given it a strong buy rating & 8 analysts have given it a buy rating. 4 analysts have given the stock a sell rating.The company posted a net profit of 1,032.56 Crores in its last quarter.Listed peers of Aurobindo Pharma include Neuland Laboratories (-1.22%), Pfizer (0.30%), Unichem Laboratories (-1.41%).The Mutual Fund holding in Aurobindo Pharma was at 16.31% in 30 Sep 2026. The MF holding has decreased from the last quarter. The FII holding in Aurobindo Pharma was at 17.41% in 30 Sep 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 16 Oct 2026, 06:02 PM IST
- BetaMedium volatility0.89Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.21The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BIn line with historical values2.55The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values25.98Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.16The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Aurobindo Pharma News
Aurobindo Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Neuland Laboratories | 19,699.70 | -1.22 | 25,177.25 | 64.28 | 12.62 | 0.18 | 13.90 |
| Pfizer | 3,819.95 | 0.30 | 17,471.29 | 27.53 | 4.97 | 1.64 | 0.86 |
| Unichem Laboratories | 512.75 | -1.41 | 3,578.88 | 54.27 | 1.53 | - | 2.40 |
| Jagsonpal Pharmaceuticals | 219.00 | -0.25 | 1,441.29 | 34.27 | 5.43 | 1.12 | 2.39 |
| Themis Medicare | 106.55 | 0.76 | 978.17 | 632.19 | 2.54 | 0.45 | 5.48 |
Mutual Fund Ownership
View allAurobindo Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-05 | Quarterly Results |
| 2026-05-21 | Audited Results |
| 2026-04-06 | Buy Back of Shares |
| 2026-02-09 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
About the company Aurobindo Pharma
- IndustryMajor Drugs
- ISININE406A01037
- BSE Code524804
- NSE CodeAUROPHARMA
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.
Aurobindo Pharma Share Price FAQs
Aurobindo Pharma is trading at 1658.65 as on Fri Oct 16 2026 09:43:39. This is -0.98% lower as compared to its previous closing price of 1675.00.
The market capitalization of Aurobindo Pharma is 95435.05 Cr as on Fri Oct 16 2026 09:43:39.
The average broker rating on Aurobindo Pharma is Buy. The breakup of analyst rating is given below -
- 8 analysts have given a strong buy rating
- 8 analysts have given a buy rating
- 5 analysts have given a hold rating
- 4 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Aurobindo Pharma is 1739.95 whereas the 52 wk low is 1080.10
Aurobindo Pharma can be analyzed on the following key metrics -
- TTM P/E: 24.67
- Sector P/E: 33.15
- Dividend Yield: 0.00%
- D/E ratio: -
Aurobindo Pharma reported a net profit of 3504.75 Cr in 2026.
The Mutual Fund Shareholding was 16.31% at the end of 30 Sep 2026.
Quick Links
EQUITY QUICK LINKS
Aurobindo Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.